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ABSTRACT
The fast increasing stroke burden across all countries
of the world suggests that currently used primary
stroke and cardiovascular disease (CVD) prevention
strategies are not sufficiently effective. In this article,
we overview the gaps in, and pros and cons of,
population-wide and high-risk prevention strategies.
We suggest that motivating and empowering people to
reduce their risk of having a stroke/CVD by using
increasingly used smartphone technologies would
bridge the gap in the population-wide and high-risk
prevention strategies and reduce stroke/CVD burden
worldwide. We emphasise that for primary stroke
prevention to be effective, the focus should be shifted
from high-risk prevention to prevention at any level of
CVD risk, with the focus on behavioural risk factors.
Such a motivational population-wide strategy could
open a new page in primary prevention of not only
stroke/CVD but also other non-communicable
disorders worldwide.
INCREASING BURDEN OF STROKE
Although the incidence and mortality rates
of stroke and other cardiovascular diseases
(CVDs) are declining,1 the absolute number
of people affected by and remaining disabled
from stroke has increased signiﬁcantly at the
global, regional and country-speciﬁc levels.
Globally, the number of deaths from stroke
has increased by 41%, incident strokes by
66% and prevalent strokes by 84%.2–4 There
is virtually no country in the world where the
absolute number of incident, fatal or preva-
lent strokes or disability-adjusted life years
(DALYs) lost associated with stroke has
decreased over that period of time.2 5
Although ageing and population growth
were shown to be the main drivers of the
increased CVD (including stroke) mortality
in the world,6 not all of the increased stroke
burden can be accounted for by these demo-
graphic changes. For example, the propor-
tional contribution of DALYs and deaths due
to stroke globally compared with all diseases
from 1990 to 2013 increased by 31% and
22%, respectively. Stroke is now no longer a
disease of the elderly, with more than 60% of
all strokes occurring in people aged
<65 years.7 8 Furthermore, in 2015, stroke
moved for the ﬁrst time from the third to
the second largest cause of DALYs in the
world.1 These changes in the proportional
contribution of stroke burden to the overall
burden from all other diseases and the trend
Key questions
What is already known about this topic?
▸ Stroke and cardiovascular disease (CVD) burden
is increasing across the globe.
▸ There are two primary prevention strategies for
stroke and CVD: mass or population-wide pre-
vention and high-risk prevention.
What are the new findings?
▸ Currently used primary stroke/cardiovascular
disease (CVD) prevention strategies are not
effective enough and there are major gaps in
primary stroke prevention strategies.
▸ Mobile technologies offer new promising ways
of bridging the gap between population-wide
and high-risk prevention strategies and enhan-
cing primary stroke/CVD prevention.
Recommendations for policy
▸ The emphasis in primary stroke/cardiovascular
disease (CVD) prevention should be shifted from
high-risk prevention to prevention at any level of
CVD risk, with the focus on behavioural risk
factors.
▸ The proposed features of mobile technology to
motivate and empower people to reduce their
risk of stroke/CVD can help to reduce stroke/
CVD burden across the globe and open up a
new, ‘motivational population-wide’, universally
accessible and effective strategy for primary pre-
vention of other major non-communicable
disorders.
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towards affecting younger populations cannot be
explained by these demographic changes alone.
Similar global negative trends were also observed for
CVD and other non-communicable disorders (NCDs)
and risk factors, especially for behavioural risk factors,
overweight and diabetes mellitus,9 10 prompting the
United Nations (UN) to develop a special NCDs
Declaration,11 followed by the WHO Global Action
Plan12 on NCDs to attain a global target of a 25% reduc-
tion in premature deaths from NCDs.13 If the current
trend in stroke burden continues, stroke will likely
become the major cause of death and disability world-
wide. Moreover, recent GBD 2015 Study estimates
demonstrated that none of the 188 participating coun-
tries currently meets all of the UN’s health-related sus-
tainable development goals (SDGs)14 and that the
median health-related SDG index in 2015 was only 56.2
(out of 100 maximum possible).
This then raises questions on the achievability of the
WHO NCDs Global Action Plan and health-related
SDGs by 2025. For example, in a recent editorial of The
Lancet, it was stated that without a rapid increase in
action, the WHO target of a 10% reduction in physical
inactivity by 2025 will not be reached.15 These large
increases in stroke/CVD burden and risk factors strongly
suggest that currently used primary stroke/CVD preven-
tion strategies are not sufﬁciently effective.5 Given the
highly preventable nature (>90%) of stroke and
CVD,9 16 17 the question is why currently used stroke/
CVD primary prevention strategies are not sufﬁciently
effective and what can be performed to improve primary
stroke/CVD prevention on individual and population
levels. Let us ﬁrst consider what primary stroke/CVD
prevention strategies are currently available, what gaps
and challenges exist with their use and what can be per-
formed to improve primary prevention.
MASS STRATEGY AND HIGH-RISK STRATEGY: PROS AND
CONS
In 1981, Geoffrey Rose laid a foundation for a mass
(population-wide) strategy18 as the most effective strategy for
primary stroke/CVD prevention. Apart from the large
population-wide effect of even a minor shift in the distribu-
tion of risk factors in the population, the huge advantage
of the primary population-wide strategy is that it allows pre-
vention of not only stroke/CVD but a wide range of other
non-communicable diseases (NCDs) that share common
risk factors, including cancer and diabetes.
However, population-wide strategy requires policy and
legislative changes that are often not supported by
major industries (eg, salt reduction in processed food,
reduction in exposure to smoking, alcohol, fast food)
and, therefore, is very difﬁcult to implement. For
example, although cigarettes were recognised as the
cause of the lung cancer epidemic in 1950 and the ﬁrst
Public Health Cigarette Smoking Act was introduced in
the USA in 1969, it took several decades before various
policies towards smoking reduction on an international
level started being implemented worldwide, and even
now smoking remains one of the largest contributors to
the burden of stroke/CVD9 16 17 and other major NCDs
in the world.10 In addition, population-wide primary pre-
vention often requires substantial investments (eg,
setting up affordable and widely accessible health
outlets, affordable healthy foods and facilities for
adequate physical activities to integrate physical activity
into our daily lives15).
Governmental actions are political decisions that often
meet resistance from the population/voters or from
non-state actors, such as industry. As acknowledged by
the UN General Assembly in 2014, there has been very
slow, insufﬁcient and uneven progress in the governmen-
tal mass strategy prevention programmes.13 All these
challenges make the population-wide primary stroke/
CVD prevention strategy very difﬁcult to implement on a
national level and, although the mass strategy was sug-
gested by Rose 35 years ago, there is still no country in
the world where this strategy is fully implemented.
Despite a special 2011 NCDs UN Declaration to have a
NCDs prevention plan in every country in 2016,11 most
countries still do not have such plan.
Since the publication of Rose’s 1981 paper and his
subsequent research on high-risk and population-wide
prevention strategies, there have been signiﬁcant
improvements in the accuracy of identiﬁcation of high
stroke/CVD risk individuals, which, as noted by
McLaren et al19 in 2009, led some to believe it was neces-
sary ‘to reduce or obviate the need for population pre-
vention strategies in favour of high-risk strategies’. Unlike
mass or population-wide primary prevention strategy
when preventive interventions (reduction in exposure to
risk factors and increase in exposure to potentially
healthy, protective factors) are introduced to the whole
population regardless of their baseline level of risk for
stroke/CVD, the high-risk prevention strategy implies
screening of the population to identify people with
increased absolute risk of stroke/CVD.20 21
In 2007, there was a ‘Head to Head’ debate in the
British Medical Journal between Jackson et al22 who
argued that screening individuals at high risk of CVD
would be effective as well as cost-effective and
Capewell23 who argued that whole population
approaches would be more cost-effective. In our
opinion, although high-risk strategy is good at taking an
integrative approach for primary stroke/CVD prevention
and can be used as a guide for making clinical decisions
on the intensity and effectiveness of preventive interven-
tions,19 24 it has a number of signiﬁcant limitations.5
Moreover, the most recent evidence has proven that
opponents of the high-risk strategies were correct. It has
recently been estimated that high-risk strategy theoretic-
ally could, at best, reduce CVD incidence by 11%,25 but
evidence from the most recent 15 randomised con-
trolled trials (over 240 000 patients, including Cochrane
Systematic Review)26 27 convincingly showed that just
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screening of the population for CVD risk, even when
combined with some counselling, is not effective at all
(compared with the current preventive strategies) for
reducing stroke/CVD incidence and mortality on a
population level.
This situation with the high-risk strategy may be
described as Rose’s ‘prevention paradox’, just the other
way around—‘a measure that brings beneﬁts to high-risk
individuals offers little to the community’. On the other
hand, evidence from the North Karelia Project and two
other subnational studies have conﬁrmed the effective-
ness of the population-wide strategy for stroke/CVD pre-
vention.28–30 However, despite this compelling body of
evidence, the high-risk approach is still being used in
preference over the population-wide approach.25
MAJOR GAPS IN PRIMARY STROKE/CVD PREVENTION
Current primary stroke prevention strategies are not suf-
ﬁciently effective,31 as there are several gaps in
prevention.
1. Lack of awareness: Despite the evidence for modifying
health behaviour,32 the level of public awareness of
stroke, its risk factors and management is low.33 This
means that behaviour modiﬁcation is suboptimal and
can (and should) be greatly enhanced;
2. Underusage of population-wide strategies: In 2008,
Capewell23 argued that the greatest danger arising
from the high-risk approach is that it is ‘misleading
professionals, planners and politicians into thinking
they can tick the mission accomplished box for pre-
venting cardiovascular disease’. The lack of use of the
population-wide prevention strategy and unreason-
ably excessive focus on high-risk prevention strategies
have been suggested as the main reasons for the lack
of efﬁciency of the currently used primary stroke/
CVD prevention;5
3. False reassurance of low risk: Current primary preven-
tion strategies recommendations primarily target
people with moderate to high absolute CVD risk.34
Individuals labelled as ‘low risk’ are falsely reassured
and not motivated to reduce their risk, despite many
having several modiﬁable risk factors. Indeed, ∼80%
of strokes occur in people categorised as having
low absolute risk.35 In a recent Editorial in the
International Journal of Epidemiology,36 Chiolero et al
wrote that “a fundamental failure of high-risk preven-
tion strategies is their inability to prevent disease in
the large part of the population at a relatively small
average risk and from which most cases of disease ori-
ginate.” Therefore, the majority of the population is
effectively left out of preventive interventions. It was
also suggested that in communicating absolute CVD
risk, categorisation of people into low, moderate
(mild) and high risk should be abandoned;5
4. Management of blood pressure: The current stroke/CVD
absolute risk assessment guidelines20 34 37 manage-
ment approach is based on overall CVD risk. Thus,
individuals with blood pressures (BP) higher than
140/90 mm Hg, which conventionally deﬁnes hyper-
tension,38 may not be treated with antihypertensive
medication because of a 5-year absolute CVD risk
below 15%.39 However, elevated BP is an important
modiﬁable risk factor and has been identiﬁed as a
leading cause of stroke/CVD burden worldwide,9 16 17
and therefore should be controlled appropriately;9
5. Important stroke risk factors missed from screening: With
the exception of smoking, behavioural risk factors
such as poor diet, sedentary lifestyle, chronic stress,
overweight and excessive alcohol intake are not
usually included in the stroke/CVD risk algorithms
that are currently used. This is despite the fact that
nearly three-quarters of the global burden of stroke
is linked to lifestyle choices.9
6. Low speciﬁcity of the CVD prediction algorithms: Most of
the currently used CVD/stroke prediction algorithms
are based on the Framingham study of a primarily
white population of North America, which may not
be accurate enough for other racial/ethnic groups.37
7. Cost barrier: Seeing a physician for a CVD risk assess-
ment is a cost barrier for some, especially for people
in low to medium-income countries, hence a low-cost
method of risk assessment is needed to address this
issue. In addition, screening programmes for identify-
ing high-risk individuals require considerable efforts
and cost, therefore unlikely to be widely implemen-
ted in resource-poor countries and socially disadvan-
taged populations, even in high-income countries.
BRIDGING THE GAP BETWEEN MASS AND HIGH-RISK
STRATEGIES
Recent advances in mobile (smartphone) technologies
and their worldwide use (about 2 billion estimated users
in 2015)40 offer unique opportunities to use these tech-
nologies for improving health and research capabil-
ities.41 In a recent Scientiﬁc Statement of the American
Heart Association (AHA) on consumer use of mobile
health for CVD prevention,42 it was stated that mobile
technologies have the potential to provide required
information to counsel and motivate individuals to
engage in behaviours to prevent CVD and ‘to transform
the delivery of health-related messages and on-going
interventions targeting behaviour change’.
In recognition of the importance of e-research NCD
initiatives, the UN Economic and Social Council, the
International Telecommunication Union (ITU) and the
WHO recently ( June 2013) launched a new mHealth
initiative for improving NCD prevention, treatment and
policy enforcement.43 However, some health profes-
sionals raised concerns about the use of mobile tech-
nologies for primary prevention, such as likely low
efﬁcacy and sustainability of the prevention effect as well
as the likely short usage of the app during the lifetime,
distraction from more effective population-wide
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prevention strategies and widening inequalities between
those who can afford smartphones and those who
cannot.
Here, we would like to address these concerns, chal-
lenge Rose’s 1981 statement18 that “we should not
expect too much (in terms of prevention) from individ-
ual health education” and suggest a new, potentially
highly effective population-wide app-based primary pre-
vention strategy that can be used not only for stroke and
CVD prevention but also for primary prevention of
other NCDs.
Low efficacy and sustainability of prevention effect
There are a number of stroke/CVD and other NCD
apps currently available in Apple Store and Google Play
and there are several smartphone-based technologies
and apps that were or are being used in clinical trials for
managing particular medical conditions and risk factors
(eg, CVD risk factor modiﬁcation, healthy behavioural
changes),44–52 with promising results. As stated by the
AHA on the issue of mobile health for CVD prevention
“the current absence of evidence should not be used as
evidence of an absence of effectiveness. Instead we need
to embrace the challenge of producing this needed evi-
dence on how effective these new technologies are and
how we can best adopt them in our practice to promote
better patient care.”42 A series of initiatives and grants to
address gaps in digital health science are currently
underway in the USA and many other countries. As to
the educational component of the apps (eg, stroke
warning signs, risk factors and how to control them
based on the well-acknowledged international guide-
lines), this component of the apps needs no further evi-
dence to be used as widely as possible.
Short usage of the app during the lifetime
This is probably the greatest challenge of the app devel-
opment that needs to be addressed. To be used regularly
for primary prevention, the app needs to be pro-actively
requested by the user and meet several criteria, includ-
ing to be easy-to-use, user-friendly, culturally appropriate,
interactive and motivate the users to use it with the right
periodicity as long as possible.
Distraction from more effective population-wide prevention
strategies
We believe that mobile technologies for primary preven-
tion should not be presented as alternatives for
population-wide or even high-risk strategies but as an
add-on tool to enhance primary prevention. Focusing
on healthy behavioural modiﬁcation, appropriate
mobile technologies do not have an issue of medicalisa-
tion associated with high-risk approach.
Widening inequalities between those who can afford
smartphones and those who cannot
This concern was correct when smartphones had only
just entered the market and were not affordable for the
majority of the population. Even in emerging and devel-
oping nations, smartphone ownership rates are rising at
an extraordinary rate, climbing from a median of 21%
in 2013 to 37% in 2015.40 The number of smartphone
users in the world is projected to reach 6.1 billion by
2020.53 Thus, delivering primary prevention information
via affordable (ideally free to download) mobile plat-
forms, especially culturally appropriate and translated
into the world’s most spoken languages, may be the
most efﬁcient strategy to reduce inequalities in health
education and primary prevention.
Low efficacy of ‘individual health education’
In his 1981 paper, Geoffrey Rose emphasised the import-
ance of motivation in achieving and sustaining healthy
behaviour, but he looked at the issue from societal per-
spective. He stated: “to inﬂuence mass behaviour we
must look to its mass determinants, which are largely
economic and social.” While the economic motivation
(eg, taxation on cigarettes, salt, sugar, alcohol, saturated
fat) and social motivation (eg, public unacceptability of
smoking and other unhealthy health behaviours and
social encouragement of healthy lifestyle/behaviour) are
very important for effective primary population-wide pre-
vention strategies, the already high and increasing usage
of smartphones throughout the world offers an add-
itional, not only motivational, but also health educa-
tional tool to enhance primary prevention on the
personal level.
In the area of stroke and CVD, one promising way of
motivating individuals to look after their health could be
by showing them their relative risk or lifetime risk37 54–56
of having a disease, which is also far easier to under-
stand by lay people than absolute risk. For example, a
White/Caucasian man aged 35 years who smokes and
has a BP of 140/85 mm Hg has 2.9% 10-year absolute
risk of CVD (myocardial infarction or stroke as
determined by ASCVD Risk Evaluation37 57 or similar
PREDICT58 algorithm), which is conventionally
regarded as mild/low risk. If this individual is told that
his risk of having CVD is mild/low, he (most likely)
would believe that he is safe from CVD and would not
be motivated to reduce his risk, even though he has two
very signiﬁcant risk factors for CVD (hypertension
and smoking) that warrant adequate preventative
interventions.
The ASCVD Risk Evaluation shows that the same indi-
vidual’s 10-year risk with optimal risk factors equals to
0.6%, meaning that the relative risk of having CVD is
almost 5. The lifetime risk of that individual is 50% and
5% with optimal risk factors, meaning that his lifetime
relative risk is 10. It would be logical to assume that if
the same individual were told that his CVD risk is 5–10
times greater than someone of his age, sex and race/
ethnicity, he would be interested to know why his risk is
so high and what he could do to reduce it. For the
purpose of motivation, it has also been recommended to
use various risk visualisation techniques.56 59 60
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WHERE TO FROM HERE?
For primary stroke prevention to be effective, the
emphasis should be shifted from high-risk prevention to
prevention at any level of CVD risk, with the focus on
behavioural risk factors. It was recently suggested that
motivating and empowering people to reduce their risk
of having a stroke/CVD using increasingly used smart-
phone technologies would bridge the gap in the
population-wide and high-risk prevention strategies and
reduce stroke/CVD burden worldwide,5 55 even in devel-
oping countries such as Africa and India,61 where owner-
ship of smartphones is already high and increasing.
Evidence of the efﬁcacy of smartphone technologies for
management and prevention of CVD and other NCDs
and risk factors is accumulating with promising
results.44–46 62–64 Capitalising on the mobile information
technology that motivates and empowers people
throughout the world to reduce their risk of having a
stroke/CVD represents a new paradigm in mass primary
prevention,65 which we suggest calling ‘motivational
population-wide strategy.’
An example of this strategy is the validated Stroke
Riskometer app,55 66–68 endorsed not only by all major
international organisations (World Stroke Organization,
World Federation of Neurology, World Heart Federation
and European Stroke Organisation) but also an increas-
ing number of national stroke organisations, including
China Stroke Association, Australian Stroke Foundation
and the National Russian Organisation for the Fight
Against Stroke. In 2014, the app was voted by senior
American doctors as the number 1 app in Medical
Conditions among 100 000 + health-related apps world-
wide,69 and since then has been downloaded >100 000
times from over 100 countries.
The app not only empowers people to know their
absolute risk (as many other CVD apps do)57 70 but also
Figure 1 Comparison of
conventional population-based,
high-risk and motivational
population-wide cardiovascular
disease (CVD) prevention
strategies. Modified from WHO
‘Cardiovascular disease
prevention and control.
Translating evidence into
action’.72 (A) Population-based
prevention strategy aimed at
shifting the distribution of risk
factors and associated CVD risk
in the whole population towards
optimal distribution of CVD risk
(shadowed in grey area shows a
theoretically possible proportion
of the population that could
benefit from this strategy); (B)
high-risk prevention strategy
aimed at treating the individuals
at high absolute risk of CVD
(shadowed in grey area shows a
theoretically possible proportion
of the population that could
benefit from this strategy; with the
20% cut-off for 10-year high CVD
risk, only about 13% of the
population could benefit from this
strategy);73 (C) motivational
population-wide CVD prevention
strategy aimed at managing CVD
risk factors in the individuals at
the high relative risk of CVD
(shadowed in grey area shows a
theoretically possible proportion
of the population that could
benefit from this strategy; with two
CVD risk factors, almost 80% of
the population could benefit from
this strategy).71
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their relative risk of having a stroke within the next 5–
10 years, thus motivating them to reduce their risk of
stroke. For example, for an 82 kg, 170 cm, man aged
25 years, with a poor diet (<6 servings of fruits/vegeta-
bles a day), not physically active enough and with systolic
BP of 127 mm Hg, the 5-year absolute risk of having a
stroke is only 0.65%. However, this man’s relative risk of
having a stroke is 2.8, and this, we believe, would motiv-
ate him to know why his risk is increased and what he
can do to reduce it. As 78% of adults free of CVD have
two or more modiﬁable CVD risk factors such as BP,
cholesterol, glucose, body mass index, smoking, physical
activity or diet,71 and therefore will have a noticeably
increased relative risk of stroke shown in the app arguably
sufﬁcient to motivate them to reduce their risk, we
believe that the effectiveness of the app in preventing
stroke and other major NCDs that share common risk
factors with stroke may be close to that of the mass strat-
egy (ﬁgure 1).65
Apart from these risk factors, the app includes add-
itional risk factors such as alcohol intake, stress, family
history of CVD and diabetes; therefore, the proportion
of adults free from CVD disease who have two or more
CVD risk factors included in the app is likely to be
noticeably >78%. The app also educates users about
stroke warning signs (extended version of the
Face-Arm-Speech-Time (F.A.S.T.)), their individual
and overall risk factors and how to control them by
using evidence-based and internationally recognised
guidelines.
Unlike some costs associated with the implementation
of population-wide primary prevention strategies and sig-
niﬁcant costs associated with screening of the population
for implementation of high-risk prevention strategies, an
app-based primary prevention strategy carries virtually
no cost and there are no counterproductive stakeholders
that may inﬂuence the individual’s decision to reduce
their risk of having a disease. It carries no risk of adverse
events and is basically a ‘nothing to lose’ strategy.
There is evidence that a combination of population-
wide and individual approach integrated into the
primary care for CVD prevention is effective in reducing
CVD mortality and also reduces socioeconomic inequal-
ities in CVD mortality.74 By taking advantage of
population-wide and high-risk prevention strategies and
at the same time addressing their current limitations,
these mobile technologies could be incorporated into
the hospital and community patient management
systems (ﬁgure 2), thus providing an important (cur-
rently missing) interface between patients and health-
care providers.
In addition, the app provides a unique research tool
for collecting much needed epidemiological data on
stroke and other major NCDs across the globe, and the
international app-based epidemiological RIBURST study
(Reducing the International Burden of Stroke Using
Mobile Technology)55 is already underway. The Stroke
Riskometer app is currently being piloted in New
Zealand in a randomised controlled trial called MARS
(Mobile Application to Reduce Risk of Stroke; ANZCTR
Trial Registration Number ACTRN12616000376448p).
Preliminary results indicate the feasibility of recruit-
ment and acceptability of the intervention by partici-
pants. Pilot ﬁndings showed that those randomised to
the intervention group used the app at least one, but up
to six, times in 3 months. The participants also provided
positive feedback on the trial experience. For example;
“That is awesome, to have an app do that. I am really
Figure 2 Integrating mobile
technology with patient
management systems.
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concerned about my health and want to do something
about it, just need a motivation”; “My mum had a stroke.
I know how it affects everyone. I want to live healthier
for my family and my children”; “I have a partner who
has had a stroke. I wasn’t with him at the time but I
want to understand it more and why it happens”; “I want
to be a good role model for my kids. I want to show
them how to live healthy and eat healthy.” These quotes
highlight the desire for people in the community to
know more about stroke and take action for better
health, and also the need for a tool that will allow them
to do so, thus proving the motivational value of the app.
The trial is expected to be completed by mid-2017.
With more than 300 collaborators in over 100 coun-
tries, the RIBURST study is one of the largest inter-
national epidemiological studies of stroke, myocardial
infarction, dementia and type 2 diabetes mellitus in the
world. The app has the potential to save millions of lives
around the world, by being translated into the world’s
most spoken languages (covering over 90% of the world
population), motivating and empowering people to
reduce their risk of not only stroke but also other major
NCDs that share common risk factors with stroke, such
as ischaemic heart disease, dementia and diabetes melli-
tus. It was suggested that improving CVD health by
improving control of CVD risk factors will also reduce
the burden of cancer and other chronic disease.75 Such
a motivational population-wide strategy could open a
new page in primary prevention of not only stroke/CVD
but also other NCDs worldwide.
In 2011, the WHO stated “The use of mobile and wire-
less technologies to support the achievement of health
objectives (mHealth) has the potential to transform the
face of health service delivery across the globe.”76 In the
most recent paper on digital health for cardiovascular
medicine published in JAMA Cardiology,77 Turakhia et al
wrote: “Digital health is still in beta testing. However, its
future is bright.” We cannot agree more!
Contributors All authors researched data for the article, made substantial
contributions to discussions of the content and reviewed and/or edited the
manuscript before submission. VLF wrote the initial draft of the article.
Funding VLF was partly funded by the Health Research Council of New
Zealand, the Brain Research New Zealand Centre of Research Excellence, the
‘Ageing Well’ Programme of the National Science Challenge and the Ministry
of Business, Innovation and Employment of New Zealand. GAM has grant
funding from the US National Institute on Ageing and Medtronic Philanthropy.
Disclaimer The views expressed in this article are those of the authors and
do not necessarily represent the views of the Centers for Disease Control and
Prevention; National Heart, Lung, and Blood Institute; National Institutes of
Health; or the US Department of Health and Human Services.
Competing interests VLF is a principal investigator of the RIBURST study
and a randomised controlled trial testing efficacy of Stroke Riskometer app for
primary stroke prevention; he has served as a speaker for AstraZeneca and
Bristol-Myers Squibb. VLF declares that the not-for-profit Stroke Riskometer
app is copyrighted by the Auckland University of Technology (New Zealand),
and any possible revenue from sales of Stroke Riskometer Pro version of the
app will be used for research and educational purposes. The other authors
declare no competing interests and have no conflicts to disclose.
Provenance and peer review Not commissioned; internally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Vos T, Allen C, Arora M, et al. Global, regional, and national
incidence, prevalence, and years lived with disability for 310
diseases and injuries, 1990–2015: a systematic analysis for the
Global Burden of Disease Study 2015. Lancet 2016;388:1545–602.
2. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global
burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD
2013 study. Neuroepidemiology 2015;45:161–76.
3. Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and
national disability-adjusted life-years (DALYs) for 315 diseases and
injuries and healthy life expectancy (HALE), 1990–2015: a
systematic analysis for the Global Burden of Disease Study 2015.
Lancet 2016;388:1603–58.
4. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life
expectancy, all-cause mortality, and cause-specific mortality for 249
causes of death, 1980–2015: a systematic analysis for the Global
Burden of Disease Study 2015. Lancet 2016;388:1459–544.
5. Feigin VL, Norrving B, George MG, et al. Prevention of stroke: a
strategic global imperative. Nat Rev Neurol 2016;12:501–12.
6. Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and
epidemiologic drivers of global cardiovascular mortality. N Engl
J Med 2015;372:1333–41.
7. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and
regional burden of stroke during 1990–2010: findings from the
Global Burden of Disease Study 2010. Lancet 2014;383:245–55.
8. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and
regional burden of first-ever ischaemic and haemorrhagic stroke
during 1990–2010: findings from the Global Burden of Disease
Study 2010. Lancet Glob Health 2013;1:e259–81.
9. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke
and risk factors in 188 countries, during 1990–2013: a systematic
analysis for the Global Burden of Disease Study 2013. Lancet
Neurol 2016;15:913–24.
10. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional,
and national comparative risk assessment of 79 behavioural,
environmental and occupational, and metabolic risks or clusters
of risks in 188 countries, 1990–2013: a systematic analysis for the
Global Burden of Disease Study 2013. Lancet 2015;386:2287–323.
11. United Nations General Assembly. Resolution adopted by the
General Assembly: 66/2: Political Declaration of the High-level
Meeting of the General Assembly on the Prevention and Control of
Non-communicable Diseases. Adopted 19 September 2011.
Published 24 January 2012. http://www.who.int/nmh/events/un_ncd_
summit2011/political_declaration_en.pdf
12. World Health Organization. Global action plan for the prevention and
control of noncommunicable diseases 2013–2020. Geneva: WHO,
2013. http://wwwwhoint/nmh/events/ncd_action_plan/en/ (4 Dec).
13. Chestnov O, Obermeyer W, St John J, et al. Towards the world we
want. Bull World Health Organ 2014;92:623.
14. Lim SS, Allen K, Bhutta ZA, et al. Measuring the health-related
Sustainable Development Goals in 188 countries: a baseline
analysis from the Global Burden if Disease Study 2015. Lancet
2016;388:1813–50.
15. Das P, Horton R. Physical activity—time to take it seriously and
regularly. Lancet 2016;388:1254–5.
16. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable
risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case-control study. Lancet 2004;364:937–52.
17. O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional
effect of potentially modifiable risk factors associated with acute
stroke in 13,447 cases and 13,472 controls in 32 countries:
INTERSTROKE case-control study. Lancet 2016;388:761–75.
18. Rose G. Strategy of prevention: lessons from cardiovascular
disease. Br Med J (Clin Res Ed) 1981;282:1847–51.
19. McLaren L, McIntyre L, Kirkpatrick S. Rose’s population strategy
of prevention need not increase social inequalities in health.
Int J Epidemiol 2010;39:372–7.
20. Alliance NVDP. Guidelines for the management of absolute
cardiovascular disease risk. Canberra: National Health and Medical
Research Council of Australia, 2012.
Feigin VL, et al. BMJ Glob Health 2017;2:e000306. doi:10.1136/bmjgh-2017-000306 7
BMJ Global Health
group.bmj.com on April 5, 2017 - Published by http://gh.bmj.com/Downloaded from 
21. Heuschmann PU, Grieve AP, Toschke AM, et al. Ethnic group
disparities in 10-year trends in stroke incidence and vascular risk
factors: the South London Stroke Register (SLSR). Stroke
2008;39:2204–10.
22. Jackson R, Wells S, Rodgers A. Will screening individuals at high
risk of cardiovascular events deliver large benefits? Yes. BMJ
2008;337:a1371.
23. Capewell S. Will screening individuals at high risk of cardiovascular
events deliver large benefits? No. BMJ 2008;337:a1395.
24. World Health Organization. Prevention of cardiovascular disease:
guidelines for assessment and management of cardiovascular risk.
Geneva: WHO, 2007.
25. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of
population and high-risk strategies for the primary prevention of
cardiovascular disease. Eur Heart J 2004;25:484–91.
26. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, et al. General
health checks in adults for reducing morbidity and mortality from
disease: Cochrane systematic review and meta-analysis. BMJ
2012;345:e7191.
27. Jørgensen T, Jacobsen RK, Toft U, et al. Effect of screening and
lifestyle counselling on incidence of ischaemic heart disease in
general population: Inter99 randomised trial. BMJ 2014;348:g3617.
28. Puska P. Successful prevention of non-communicable diseases: 25
year experiences with North Karelia project in Finland. Public Health
Med 2002;4:5–7.
29. Miura K. Epidemiology and prevention of hypertension in Japanese:
how could Japan get longevity? EPMA J 2011;2:59–64.
30. Record NB, Onion DK, Prior RE, et al. Community-wide
cardiovascular disease prevention programs and health outcomes in
a rural county, 1970–2010. JAMA 2015;313:147–55.
31. Ebrahim S, Taylor F, Ward K, et al. Multiple risk factor interventions
for primary prevention of coronary heart disease. Cochrane
Database Syst Rev 2011;(1):CD001561.
32. Spring B, Ockene JK, Gidding SS, et al. Better population health
through behavior change in adults: a call to action. Circulation
2013;128:2169–76.
33. Jones SP, Jenkinson AJ, Leathley MJ, et al. Stroke knowledge and
awareness: an integrative review of the evidence. Age Ageing
2010;39:11–22.
34. Group NZG, editor. New Zealand primary care handbook. 3rd edn.
Wellington: New Zealand Guidelines Group, 2012.
35. Dalton ARH, Soljak M, Samarasundera E, et al. Prevalence of
cardiovascular disease risk amongst the population eligible for the
NHS Health Check Programme. Eur J Prev Cardiol 2013;20:142–50.
36. Chiolero A, Paradis G, Paccaud F. The pseudo-high-risk prevention
strategy. Int J Epidemiol 2015;44:1469–73.
37. Goff DCJr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA
guideline on the assessment of cardiovascular risk: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice guidelines. J Am Coll Cardiol 2014;63(25 Part
B):2935–59.
38. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based
guideline for the management of high blood pressure in adults:
report from the panel members appointed to the Eighth Joint
National Committee ( JNC 8). JAMA 2014;311:507–20.
39. McLean RM, Williams S, Mann JI, et al. Blood pressure and
hypertension in New Zealand: results from the 2008/09 Adult
Nutrition Survey. N Z Med J 2013;126:66–79.
40. Pew Research Center. Global Attitudes & Trends. Smartphone
Ownership and Internet Usage Continues to Climb in Emerging
Economies. 2016. http://www.pewglobal.org/2016/02/22/smartphone-
ownership-and-internet-usage-continues-to-climb-in-emerging-
economies/
41. Nasser FB, Trevena L. There’s an app for that: a guide for
healthcare practitioners and researchers on smartphone technology.
Online J Public Health Inform 2015;7:e218.
42. Burke LE, Ma J, Azar KMJ, et al. Current science on consumer use
of mobile health for cardiovascular disease prevention: a scientific
statement from the American Heart Association. Circulation
2015;132:1157–213.
43. BE HE@LTHY, BE MOBILE 2014. http://www.itu.int/en/ITU-D/ICT-
Applications/eHEALTH/Pages/Be_Healthy.aspx
44. Buller DB, Borland R, Bettinghaus EP, et al. Randomized trial of a
smartphone mobile application compared to text messaging to
support smoking cessation. Telemed J E Health 2013;20:206–14.
45. Carter MC, Burley VJ, Nykjaer C, et al. Adherence to a smartphone
application for weight loss compared to website and paper diary:
pilot randomized controlled trial. J Med Internet Res 2013;15:e32.
46. Chow CK, Redfern J, Hillis GS, et al. Effect of lifestyle-focused text
messaging on risk factor modification in patients with coronary heart
disease: a randomized clinical trial. JAMA 2015;314:1255–63.
47. Ganesan AN, Louise J, Horsfall M, et al. International
mobile-health intervention on physical activity, sitting, and weight:
the Stepathlon Cardiovascular Health Study. J Am Coll Cardiol
2016;67:2453–63.
48. Urrea B, Misra S, Plante TB, et al. Mobile health initiatives to
improve outcomes in primary prevention of cardiovascular disease.
Curr Treat Options Cardiovasc Med 2015;17
49. Piette JD, List J, Rana GK, et al. Mobile health devices as tools for
worldwide cardiovascular risk reduction and disease management.
Circulation 2015;132:2012–27.
50. Pfaeffli Dale L, Dobson R, Whittaker R, et al. The effectiveness of
mobile-health behaviour change interventions for cardiovascular
disease self-management: a systematic review. Eur J Prev Cardiol
2015;23:801–17.
51. Surka S, Edirippulige S, Steyn K, et al. Evaluating the use of
mobile phone technology to enhance cardiovascular disease
screening
by community health workers. Int J Med Inform 2014;83:648–54.
52. Chan CV, Kaufman DR. Mobile phones as mediators of health
behavior change in cardiovascular disease in developing countries.
Stud Health Technol Inform 2009;143:453–8.
53. Digital Trends. The number of smartphone users in the world is
expected to reach a giant 6.1 billion by 2020. http://www.
digitaltrends.com/mobile/
smartphone-users-number-6-1-billion-by-2020/. 2016.
54. Cooney MT, Dudina A, D’Agostino R, et al. Cardiovascular
risk-estimation systems in primary prevention: do they differ? Do
they make a difference? Can we see the future? Circulation
2010;122:300–10.
55. Feigin VL, Krishnamurthi R, Bhattacharjee R, et al. New
strategy to reduce the global burden of stroke. Stroke
2015;46:1740–7.
56. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines
for the management of arterial hypertension: the Task Force for the
management of arterial hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology
(ESC). J Hypertens 2013;31:1281–357.
57. Gluckman TJ, Kovacs RJ, Stone NJ, et al. The ASCVD risk
estimator app: from concept to the current state. J Am Coll Cardiol
2016;67:350–2.
58. Riddell T, Wells S, Jackson R, et al. Performance of Framingham
cardiovascular risk scores by ethnic groups in New Zealand:
PREDICT CVD-10. N Z Med J 2010;123:50–61.
59. Hill S, Spink J, Cadilhac D, et al. Absolute risk representation in
cardiovascular disease prevention: comprehension and preferences
of health care consumers and general practitioners involved in a
focus group study. BMC Public Health 2010;10:108.
60. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide:
ten steps to better risk communication. J Natl Cancer Inst
2011;103:1436–43.
61. African Health Observatory World Health Organization [Internet].
(cited 10 March 2015). https://www.aho.afro.who.int/en/blog/2015/03/
10/mobile-health-transforming-face-health-service-delivery-african-
region
62. Licskai C, Sands TW, Ferrone M. Development and pilot testing
of a mobile health solution for asthma self-management: asthma
action plan smartphone application pilot study. Can Respir J
2013;20:301–6.
63. Ly KH, Carlbring P, Andersson G. Behavioral activation-based
guided self-help treatment administered through a smartphone
application: study protocol for a randomized controlled trial. Trials
2012;13:62.
64. Jenkins C, Burkett N-S, Ovbiagele B, et al. Stroke patients and their
attitudes toward mHealth monitoring to support blood pressure
control and medication adherence. mHealth 2016;2:24.
65. Feigin VL, Norrving B. A new paradigm for primary prevention
strategy in people with elevated risk of stroke. Int J Stroke
2014;9:624–6.
66. Norrving B, Davis SM, Feigin VL, et al. Stroke prevention
worldwide—what could make it work. Neuroepidemiology
2015;45:215–20.
67. Parmar P, Krishnamurthi R, Ikram MA, et al. The Stroke
Riskometer™ app: validation of a data collection tool and stroke risk
predictor. Int J Stroke 2015;10:231–44.
68. Morgan J. The power of the App: can mobile-technology save lives?
Lancet Neurol 2015;15:668.
69. Doctors Choose the Best Health Apps of 2014. HealthTap. http://
www.healthtap.com/top_health_apps_2014
70. Ordúñez P, Tajer C. Disseminating cardiovascular disease risk
assessment with a PAHO mobile app: a public eHealth intervention.
Rev Panam Salud Publica 2015;38:82–5.
8 Feigin VL, et al. BMJ Glob Health 2017;2:e000306. doi:10.1136/bmjgh-2017-000306
BMJ Global Health
group.bmj.com on April 5, 2017 - Published by http://gh.bmj.com/Downloaded from 
71. Kulshreshtha A, Vaccarino V, Judd SE, et al. Life’s simple 7 and risk
of incident stroke: the reasons for geographic and racial differences
in stroke study. Stroke 2013;44:1909–14.
72. Cardiovascular disease prevention and control. Translating evidence
into practice. Geneva: World Health Organization, 2005.
73. Neil HAW, Perera R, Armitage JM, et al. Estimated 10-year
cardiovascular risk in a British population: results of a national
screening project. Int J Clin Pract 2008;62:1322–31.
74. Blomstedt Y, Norberg M, Stenlund H, et al. Impact of a combined
community and primary care prevention strategy on all-cause and
cardiovascular mortality: a cohort analysis based on 1 million
person-years of follow-up in Västerbotten County, Sweden, during
1990–2006. BMJ Open 2015;5:e009651.
75. Ogunmoroti O, Allen NB, Cushman M, et al. Association between life’s
simple 7 and noncardiovascular disease: the multi-ethnic study of
atherosclerosis. J Am Heart Assoc 2016;5:e003954.
76. World Health Organization. mHealth: new horizons for health
through mobile technologies. Global observatory for eHealth series.
Vol. 3. Geneva: WHO, 2011:1–99.
77. Turakhia MP, Desai SA, Harrington RA. The outlook of digital health
for cardiovascular medicine: challenges but also extraordinary
opportunities. JAMA Cardiol 2016;1:743–4.
Feigin VL, et al. BMJ Glob Health 2017;2:e000306. doi:10.1136/bmjgh-2017-000306 9
BMJ Global Health
group.bmj.com on April 5, 2017 - Published by http://gh.bmj.com/Downloaded from 
in stroke prevention
strategies: insights from using smartphones
through population-wide motivational 
Primary prevention of cardiovascular disease
Valery L Feigin, Bo Norrving and George A Mensah
doi: 10.1136/bmjgh-2017-000306
2017 2: BMJ Glob Health 
 http://gh.bmj.com/content/2/2/e000306
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://gh.bmj.com/content/2/2/e000306
This article cites 64 articles, 24 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (352)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 5, 2017 - Published by http://gh.bmj.com/Downloaded from 
